Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 10/20 | 0.52 |
| ▸ | DRD2 | P14416 | 9/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13190970 | 0.94 | DRD2 (0.51) | DRD3DRD2ALOX5PYGLSMN1; SMN2 | |
| SCHEMBL13691792 | 0.94 | DRD2 (0.52) | DRD3DRD2ALOX5PYGLSMN1; SMN2 | |
| SCHEMBL13691795 | 0.87 | DRD3 (0.47) | DRD3DRD2ALOX5PYGLOPRL1 | |
| SCHEMBL13190971 | 0.84 | MC4R (0.48) | DRD3DRD2KMT2A | |
| SCHEMBL13188833 | 0.82 | DRD2 (0.46) | DRD3DRD2ALOX5PYGLSMN1; SMN2 | |
| SCHEMBL13691856 | 0.81 | DRD2 (0.47) | DRD3DRD2ALOX5PYGLKMT2A | |
| SCHEMBL13689519 | 0.80 | LMNA (0.48) | SMN1; SMN2KMT2A | |
| SCHEMBL13689399 | 0.80 | LMNA (0.43) | SMN1; SMN2KMT2A | |
| SCHEMBL13689526 | 0.80 | SMYD2 (0.45) | DRD3DRD2KMT2A | |
| SCHEMBL13689521 | 0.79 | OPRK1 (0.51) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009105824-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2009-09-03 | — | — | WO | disclosed |